TC LAND EXPRESSION has a total of 15 patent applications. Its first patent ever was published in 2007. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets biotechnology and pharmaceuticals are ZINFANDEL PHARMACEUTICALS INC, EXPRESSION DIAGNOSTICS INC and INTEGRAGEN SA.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 6 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | Canada | 2 | |
#4 | China | 1 | |
#5 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Measuring microorganism processes | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Braud Christophe | 8 |
#2 | Soulillou Jean-Paul | 7 |
#3 | Brouard Sophie | 7 |
#4 | Cervino Alessandra | 7 |
#5 | Popa-Nita Oana Ruxandra | 5 |
#6 | Ashton-Chess Joanna | 5 |
#7 | Racape Maud | 4 |
#8 | Giral Magali | 4 |
#9 | Guillet Marina | 4 |
#10 | Giral-Classe Magali | 3 |
Publication | Filing date | Title |
---|---|---|
EP2668287A2 | Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from rheumatoid arthritis to tnf-alpha blocking monoclonal antibody | |
WO2011117366A2 | Genes and genes combinations predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd) | |
WO2010142751A1 | In vitro diagnosis/prognosis method and kit for assessment of chronic antibody mediated rejection in kidney transplantation | |
WO2010136576A1 | In vitro diagnosis/prognosis method and kit for assessment of tolerance in liver transplantation | |
WO2008138928A2 | Diagnostic of immune graft tolerance | |
EP2031073A1 | Diagnostic of immune graft tolerance using TMTC3 gene expression levels |